[HTML][HTML] Therapeutic strategies for COVID-19: progress and lessons learned
G Li, R Hilgenfeld, R Whitley, E De Clercq - Nature Reviews Drug …, 2023 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
[HTML][HTML] Mitogen activated protein kinase (MAPK) activation, p53, and autophagy inhibition characterize the severe acute respiratory syndrome coronavirus 2 (SARS …
AM Kyriakopoulos, G Nigh, PA McCullough, S Seneff - Cureus, 2022 - ncbi.nlm.nih.gov
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein and
prions use common pathogenic pathways to induce toxicity in neurons. Infectious prions …
prions use common pathogenic pathways to induce toxicity in neurons. Infectious prions …
Two antibodies show broad, synergistic neutralization against SARS-CoV-2 variants by inducing conformational change within the RBD
H Sun, T Deng, Y Zhang, Y Lin, Y Jiang, Y Jiang… - Protein & …, 2024 - academic.oup.com
Continual evolution of the severe acute respiratory syndrome coronavirus (SARS-CoV-2)
virus has allowed for its gradual evasion of neutralizing antibodies (nAbs) produced in …
virus has allowed for its gradual evasion of neutralizing antibodies (nAbs) produced in …
[HTML][HTML] Broad strategies for neutralizing SARS-CoV-2 and other human coronaviruses with monoclonal antibodies
Z Ling, C Yi, X Sun, Z Yang, B Sun - Science China Life Sciences, 2023 - Springer
Antibody therapeutics and vaccines for coronavirus disease 2019 (COVID-19) have been
approved in many countries, with most being developed based on the original strain of …
approved in many countries, with most being developed based on the original strain of …
[HTML][HTML] Non-overlapping epitopes on the gHgL-gp42 complex for the rational design of a triple-antibody cocktail against EBV infection
Epstein-Barr virus (EBV) is closely associated with cancer, multiple sclerosis, and post-acute
coronavirus disease 2019 (COVID-19) sequelae. There are currently no approved …
coronavirus disease 2019 (COVID-19) sequelae. There are currently no approved …
Structural basis for broad neutralization of human antibody against Omicron sublineages and evasion by XBB variant
H Sun, Y Wang, X Chen, Y Jiang, S Wang… - Journal of …, 2023 - Am Soc Microbiol
The continuous emergence of SARS-CoV-2 variants, particularly the newly circulating
Omicron XBB subvariants, has led to a significant reduction in the neutralizing potency and …
Omicron XBB subvariants, has led to a significant reduction in the neutralizing potency and …
[HTML][HTML] Synergistic effect of two human-like monoclonal antibodies confers protection against orthopoxvirus infection
H Tamir, T Noy-Porat, S Melamed… - Nature …, 2024 - nature.com
The eradication of smallpox was officially declared by the WHO in 1980, leading to
discontinuation of the vaccination campaign against the virus. Consequently, immunity …
discontinuation of the vaccination campaign against the virus. Consequently, immunity …
[HTML][HTML] Deciphering a reliable synergistic bispecific strategy of rescuing antibodies for SARS-CoV-2 escape variants, including BA. 2.86, EG. 5.1, and JN. 1
Z Tong, J Tong, W Lei, Y Xie, Y Cui, G Jia, S Li… - Cell Reports, 2024 - cell.com
The game between therapeutic monoclonal antibodies (mAbs) and continuously emerging
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has favored the …
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has favored the …
Screening and optimization of shark nanobodies against SARS-CoV-2 spike RBD
X Liu, Y Wang, L Sun, G Xiao, N Hou, J Chen, W Wang… - Antiviral Research, 2024 - Elsevier
SARS-CoV-2 continues to threaten human health, antibody therapy is one way to control the
infection. Because new SARS-CoV-2 mutations are constantly emerging, there is an urgent …
infection. Because new SARS-CoV-2 mutations are constantly emerging, there is an urgent …
[HTML][HTML] Broadly neutralizing antibodies targeting a conserved silent face of spike RBD resist extreme SARS-CoV-2 antigenic drift
Developing broad coronavirus vaccines requires identifying and understanding the
molecular basis of broadly neutralizing antibody (bnAb) spike sites. In our previous work, we …
molecular basis of broadly neutralizing antibody (bnAb) spike sites. In our previous work, we …